IP Library Granted Patent US 9,034,578
Granted Patent B2
US 9,034,578 · App. 14/509,022 · Granted May 19, 2015

Nucleic acid sample preparation

Inventors: Rajaram Krishnan (San Diego, CA); David Charlot (San Diego, CA); Eugene Tu (San Diego, CA); James McCanna (San Diego, CA); Lucas Kumosa (Centennial, CO); Paul Swanson (Santee, CA); Robert Turner (San Diego, CA); Kai Yang (San Diego, CA); Irina Dobrovolskaya (San Diego, CA); David Liu (San Diego, CA)
Assignee: BIOLOGICAL DYNAMICS, INC.
C12N15/1003G01N27/447G01N27/44704C12Q1/6806
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,034,578
App. No.
14/509,022
Granted
May 19, 2015
Kind
B2
Abstract

The present invention includes methods, devices and systems for isolating a nucleic acid from a fluid comprising cells. In various aspects, the methods, devices and systems may allow for a rapid procedure that requires a minimal amount of material and/or results in high purity nucleic acid isolated from complex fluids such as blood or environmental samples.

Claims (31)

1. A method for isolating a nanoparticulate in a sample, the method comprising:

a. applying the sample to a device, the device comprising an array of electrodes capable of establishing an AC electrokinetic field region;

b. concentrating cells or other particulate material in the fluid in a first AC electrokinetic field region, wherein the conductivity of the fluid is 100 mS/m or greater;

c. isolating the nanoparticulate in a second AC electrokinetic field region, wherein the second AC electrokinetic field is a second dielectrophoretic high field region; and

d. flushing the concentrated cells and/or other particulate material from the first AC electrokinetic field region.

2. The method of claim 1 , wherein the nanoparticulate comprises high molecular weight nucleic acids, high molecular weight DNA, smaller DNA, aggregated proteins, cellular debris, RNA, viruses or combinations thereof.

3. The method of claim 1 , wherein detection of the nanoparticulate provides information useful for cancer diagnosis, cancer prognosis or treatment response in a patient.

4. The method of claim 3 , wherein detection of the nanoparticulate is part of a medical therapeutic or diagnostic procedure.

5. The method of claim 1 , further comprising eluting the nanoparticulate isolated in the second dielectrophoretic high field region for further characterization.

6. The method of claim 1 , wherein the sample is whole blood, serum, plasma, cerebrospinal fluid, body tissue, urine or saliva.

7. The method of claim 1 , wherein the sample is blood.

8. The method of claim 1 , wherein the AC electrokinetic field is produced using an alternating current having a voltage of 1 volt to 40 volts peak-peak, and/or a frequency of 5 Hz to 5,000,000 Hz and duty cycles from 5% to 50%.

9. The method of claim 1 , wherein the conductivity of the fluid is 500 mS/m or greater.

10. The method of claim 1 , wherein the array of electrodes is spin-coated with a hydrogel having a thickness between about 0.1 microns and 1 micron.

11. The method of claim 10 , wherein the hydrogel comprises two or more layers of a synthetic polymer.

12. The method of claim 10 , wherein the hydrogel has a viscosity between about 0.5 cP to about 5 cP prior to spin-coating.

13. The method of claim 10 , wherein the hydrogel has a conductivity between about 0.1 S/m to about 1.0 S/m.

14. The method of claim 1 , wherein the array of electrodes comprises a wavy line configuration, wherein the configuration comprises a repeating unit comprising the shape of a pair of dots connected by linker, wherein the linker tapers inward toward the midpoint between the pair of dots, wherein the diameters of the dots are the widest points along the length of the repeating unit, wherein the edge to edge distance between a parallel set of repeating units is equidistant, or roughly equidistant.

15. The method of claim 1 , wherein the array of electrodes comprises a passivation layer with a relative electrical permittivity from about 2.0 to about 4.0.

16. A method for isolating a nanoparticulate in a sample, the method comprising:

a. applying the sample to a device, the device comprising an array of electrodes capable of establishing an AC electrokinetic field region;

b. concentrating cells or other particulate material in the fluid in a first AC electrokinetic field region, wherein the conductivity of the fluid is 100 mS/m or greater;

c. isolating the nanoparticulate in a second AC electrokinetic field region, wherein the second AC electrokinetic field is a second dielectrophoretic high field region;

d. flushing the concentrated cells and/or other particulate material from the first AC electrokinetic field region; and

e. eluting the bound nanoparticulate in the second dielectrophoretic high field region.

17. The method of claim 16 , wherein the nanoparticulate comprises high molecular weight nucleic acids, high molecular weight DNA, smaller DNA, aggregated proteins, cellular debris, RNA, viruses or combinations thereof.

18. The method of claim 16 , wherein detection of the nanoparticulate provides information useful for cancer diagnosis, cancer prognosis or treatment response in a patient.

19. The method of claim 18 , wherein detection of the nanoparticulate is part of a medical therapeutic or diagnostic procedure.

20. The method of claim 16 , wherein the sample is whole blood, serum, plasma, cerebrospinal fluid, body tissue, urine or saliva.

21. The method of claim 20 , wherein the sample is blood.

22. The method of claim 16 , wherein the AC electrokinetic field is produced using an alternating current having a voltage of 1 volt to 40 volts peak-peak, and/or a frequency of 5 Hz to 5,000,000 Hz and duty cycles from 5% to 50%.

Assignments (3)
SECURITY INTEREST Recorded Jun 12, 2024
From: BIOLOGICAL DYNAMICS, INC.
To: THE JACOBS FAMILY TRUST DATED JUNE 2, 1980, SEPARATE PROPERTY OF IRWIN MARK JACOBS
Reel/Frame 067712/0940 →
SECURITY INTEREST Recorded Mar 2, 2023
From: BIOLOGICAL DYNAMICS, INC.
To: PARIAN ZEUS LP, IN ITS CAPACITY AS COLLATERAL AGENT ON BEHALF OF THE SECURED PARTIES
Reel/Frame 062917/0195 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 21, 2015
From: KRISHNAN, RAJARAM; CHARLOT, DAVID; TU, EUGENE; MCCANNA, JAMES; KUMOSA, LUCAS; SWANSON, PAUL; TURNER, ROBERT; YANG, KAI; DOBROVOLSKAYA, IRINA; LIU, DAVID
To: BIOLOGICAL DYNAMICS, INC.
Reel/Frame 034780/0430 →
Continuity (4)
Continuation 14067841 · Oct 30, 2013
Continuation 13864179 · Apr 16, 2013
Provisional Application 61624897 · Apr 16, 2012
Related Publication 20150083595A1 · Mar 26, 2015